| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,520,000 |
| Market
Cap: |
63.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4425 - $0.4425 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
| Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
| Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
| Total People Sold |
0 |
6 |
7 |
7 |
| Total Sell Transactions |
0 |
24 |
32 |
32 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2021-06-14 |
4 |
D |
$9.72 |
$4,053 |
D/D |
(417) |
12,595 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2021-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,420 |
13,012 |
|
- |
|
| Ando Goran |
|
– • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,150 |
2,150 |
|
- |
|
| Godshall Douglas Evan |
|
– • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,900 |
5,516 |
|
- |
|
| Dicicco Wendy F |
|
– • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2021-02-28 |
4 |
D |
$10.81 |
$15,383 |
D/D |
(1,423) |
11,592 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
13,015 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,467 |
109,046 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2021-02-28 |
4 |
D |
$10.81 |
$18,399 |
D/D |
(1,702) |
7,380 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
9,082 |
|
- |
|
| Landis John B. |
|
– • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,900 |
5,900 |
|
- |
|
| Guyer David R |
|
– • – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,900 |
1,900 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2021-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,717 |
96,579 |
|
- |
|
| Liu Ye |
Director |
– • – |
2020-12-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,010,722 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2020-09-04 |
4 |
B |
$0.48 |
$4,800 |
D/D |
10,000 |
40,000 |
0.01 |
-10% |
|
| Elston George |
Chief Financial Officer |
• – – |
2020-08-24 |
4 |
B |
$0.61 |
$6,112 |
D/D |
10,000 |
30,000 |
0.01 |
-27% |
|
| Lurker Nancy |
President & CEO |
• • – |
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
124,667 |
784,467 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2020-06-30 |
4 |
D |
$0.76 |
$9,121 |
D/D |
(12,049) |
89,144 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
41,050 |
101,193 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2020-06-30 |
4 |
D |
$0.76 |
$10,643 |
D/D |
(14,060) |
26,990 |
|
- |
|
| Jones David Scott |
SVP & Chief Commercial Officer |
• – – |
2020-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
41,050 |
41,050 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2020-06-27 |
4 |
D |
$0.79 |
$2,317 |
D/D |
(2,936) |
60,143 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2020-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
63,079 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2020-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
659,800 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2020-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,000 |
619,800 |
|
- |
|
268 Records found
|
|
Page 6 of 11 |
|
|
